Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
For the fastest way to join Tom's Guide Club enter your email below. We'll send you a confirmation and sign you up to our newsletter to keep you updated on all the latest news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results